See every side of every news story
Published loading...Updated

Switch to Tirzepatide in T2D More Effective Than Upping Dulaglutide Dose

Summary by MedPage Today
(MedPage Today) -- Diabetes patients on dulaglutide (Trulicity) had better glycemic control and more weight loss if they switched to tirzepatide (Mounjaro) rather than increasing the dose of the earlier-generation GLP-1 receptor agonist, an open...

9 Articles

All
Left
Center
1
Right
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

European Medical Journal broke the news in on Thursday, April 3, 2025.
Sources are mostly out of (0)

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.